FORM
6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca begins trading on NYSE
02 February 2026
AstraZeneca begins trading on the New York Stock
Exchange
Ordinary shares now trade across the NYSE, LSE and
STO under a
harmonised global listing structure
AstraZeneca today begins trading its ordinary shares on the New
York Stock Exchange (NYSE) for the first time, enabling more US
investors to participate in the Company's strong growth. With this
change the trading of AstraZeneca ordinary shares is now aligned
across the NYSE, the London Stock Exchange (LSE) and Nasdaq
Stockholm (STO) under a harmonised listing structure.
Michel Demaré, Chair, AstraZeneca, said: "Today marks the
start of an exciting new period for AstraZeneca, one which we
believe gives broader access to the largest capital market in the
world. This will allow even more investors to participate in
AstraZeneca's future. Our harmonised listing across New York,
London and Stockholm reflects strong shareholder support for our
growth strategy and positions AstraZeneca to deliver more
innovative medicines to more patients around the
world."
Lynn Martin, President, NYSE Group said: "Today we are proud to
welcome AstraZeneca to the NYSE, where it joins a community of
groundbreakers and industry leaders. Through its listing on the
world's largest and most liquid capital market, the company is
well-positioned to expand its global investor base and accelerate
its commitment to delivering innovation to patients and the wider
biopharmaceutical industry."
AstraZeneca's strong growth is driven both by its global reach and
diverse sources of business. Last year was a catalyst-rich period
with new pipeline readouts collectively representing a peak revenue
opportunity of over $10 billion. With this momentum continuing into
2026, the Company has confidence in reaching its 2030 ambition to
grow annual revenue to $80bn and launch 20 new medicines. Looking
beyond 2030, AstraZeneca is investing in transformative
technologies that have the potential to change the practice of
medicine across our portfolio.
AstraZeneca ordinary shares will continue to trade under the ticker
symbol "AZN" across the three exchanges. The
Company's listing in the UK on the LSE and in Sweden on the
STO are unaffected by the move and remain included in the FTSE
100 and OMX Stockholm 30 indices.
The prior listing of American Depositary Shares and the various US
dollar bonds issued by the Company and AstraZeneca Finance LLC
(AstraZeneca US Bonds) on Nasdaq in the US ceased on 30
January 2026. Trading of the AstraZeneca US Bonds on the NYSE
will commence immediately following the start of trading of the
ordinary shares on the NYSE.
Notes
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
The contents of AstraZeneca's website do not form part of this
document and no one should rely on such websites or the contents
thereof in reading this document.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 02 February 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|